Skip to Content
Morningstar

iShares Core S&P 500 ETF IVV

Morningstar Medalist Rating
Medalist Rating as of | See iShares Investment Hub

Morningstar’s Analysis IVV

Will IVV outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable IVV’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the IVV management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of IVV’s parent organization’s priorities and whether they’re in line with investors’ interests.

Best-in-class option for large-cap Investors.

Associate Analyst Mo'ath Almahasneh

Mo'ath Almahasneh

Associate Analyst

Summary

iShares Core S&P 500 funds offer well-diversified, market-cap-weighted portfolios of 500 of the largest U.S. stocks. The funds accurately represent the large-cap opportunity set while charging rock-bottom fees, a recipe for success over the long run.

by Mo'ath Almahasneh
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings IVV

More IVV Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 36.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Microsoft Corp

7.19 34.2 Bil
Technology

NVIDIA Corp

7.13 33.8 Bil
Technology

Apple Inc

6.75 32.0 Bil
Technology

Amazon.com Inc

3.67 17.4 Bil
Consumer Cyclical

Meta Platforms Inc Class A

2.43 11.5 Bil
Communication Services

Alphabet Inc Class A

2.28 10.8 Bil
Communication Services

Alphabet Inc Class C

1.93 9.1 Bil
Communication Services

Broadcom Inc

1.67 7.9 Bil
Technology

Berkshire Hathaway Inc Class B

1.61 7.7 Bil
Financial Services

Eli Lilly and Co

1.53 7.3 Bil
Healthcare